Synonyms: LRX-15 | Remodulin® | Tyvaso®
treprostinil is an approved drug (FDA (2002), EMA (2020))
Compound class:
Synthetic organic
Comment: Marketed formulations may contain treprostinil diolamine (PubChem CID 11179459) or treprostinil sodium (PubChem CID 23663413).
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Syed NI, Jones RL. (2015)
Assessing the agonist profiles of the prostacyclin analogues treprostinil and naxaprostene, particularly their DP₁ activity. Prostaglandins Leukot Essent Fatty Acids, 95: 19-29. [PMID:25542069] |
2. Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, Allen R, Feldman J, Argula R, Smith P et al.. (2021)
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med, 384 (4): 325-334. [PMID:33440084] |
3. Whittle BJ, Silverstein AM, Mottola DM, Clapp LH. (2012)
Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol, 84 (1): 68-75. [PMID:22480736] |